The advanced, metastatic differentiated thyroid cancers (DTCs) have a poor prognosis
mainly owing to radioactive iodine (RAI) refractoriness caused by decreased expression of …

Recurrent, metastatic disease represents the most frequent cause of death for patients with
thyroid cancer, and radioactive iodine (RAI) remains a mainstay of therapy for these patients …

Simple Summary The Ras-Raf-MEK-ERK signaling pathway is responsible for regulating
cell proliferation, differentiation and survival. Overexpression and overactivation of members …

Backgrounds Papillary thyroid cancer (PTC), which is often driven by acquired somatic
mutations in BRAF genes, is the most common pathologic type of thyroid cancer. PTC has …

Thyroid cancer is the most prevalent endocrine tumor and its incidence is fast-growing
worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common …

Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) is difficult to treat with
radioactive iodine because of the absence of the sodium iodide transporter in the basement …

The retained functionality of the sodium iodide symporter (NIS) expressed in differentiated
thyroid cancer (DTC) cells allows the further utilization of post-surgical radioactive iodine …

The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …

Differentiated thyroid cancer (DTC) is usually curable with surgery, radioactive iodine (RAI),
and thyroid-stimulating hormone (TSH) suppression. However, local recurrence and/or …

Based on experimental data, the inhibition of the MAPkinase pathway in patients with
radioiodine-refractory thyroid cancer was capable of inducing a redifferentiation. Preliminary …